Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 23;107(8):1746–1757. doi: 10.3324/haematol.2021.279410

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 7. — Simultaneous and not sequential treatment of palbociclib with cytotoxic chemotherapy significantly inhibits disease burden in one T-cell acute lymphoblastic leukemia sample in vivo. (A) Schematic representation of CDK inhibitors (CDKi) and vincristine (VCR) combination regimen in a T-cell acute lymphoblastic leukemia (T-ALL) xenograft (Cul76). Peripheral blood is taken at specific time points as shown. (B) Flow cytometry analysis of peripheral blood analysis of human primary T-ALL patient-derived xenograft (PDX), Cul76, following palbociclib (palbo) treatment. (C) Kaplan-Meier survival graph of T-ALL PDX treated with the combination therapy regimen over a period of 42 days.